Vegas—Vermont’s 2026 legislative overhaul finally tipped the scales: adults 21 and older can now legally possess up to two grams of dried psilocybin mushrooms without facing criminal prosecution. The change, enacted through Act 190 (2026) and codified at 13 Vt. Rt. § 71‑2, eliminated the misdemeanor charge that previously applied to small‑scale possession, while still prohibiting sales, large‑scale cultivation, and any activity that puts users at risk. The law reflects a growing national trend toward regulated psychedelic access, yet it coexists with unchanged federal restrictions that keep psilocybin on Schedule I.
Legal Landscape After 2026 Amendments
Act 190 amended Vermont’s controlled substances schedule, moving limited personal possession of psilocybin mushrooms from a Schedule III offense to a non‑criminal civil violation. Penalties for possession under two grams are now a $50 fine, payable to the state, and do not result in a criminal record. Possession of larger amounts, the intent to sell, or cultivation of mushrooms beyond personal use remains a felony under 13 Vt. Rt. § 71‑3. The statute also requires the Department of Health to develop guidelines for safe consumption, though those guidelines have yet to be published.
What the Law Means for Residents and Visitors
For Vermont residents, the reform translates into immediate de‑criminalization of modest personal use. A resident who is 21 or older and possesses up to two grams can keep the mushrooms in a sealed container without fear of arrest. Visitors are subject to the same statutory limits; however, law‑enforcement officials retain discretion to seize substances if they suspect distribution or unsafe handling. Importantly, the law does not create a commercial market—selling or supplying mushrooms is still a felony, and no licensed dispensaries exist as of this writing.
Federal vs State Conflict
Psilocybin remains classified as a Schedule I substance under the Controlled Substances Act. Consequently, federal agents retain authority to enforce federal law even within Vermont’s borders. While state prosecutors will no longer initiate criminal cases for small‑scale possession, a federal indictment could still be pursued if the drug enters interstate commerce or is linked to a federal investigation. Experts warn that the dual legal framework may create uncertainty for users who travel across state lines.
Frequently Asked Questions
Can a minor possess psilocybin mushrooms under the new law?
No. The de‑criminalization applies only to individuals 21 years of age or older. Minors caught with any amount remain subject to the original misdemeanor provisions and may face juvenile court proceedings.
Are there any licensing requirements for growing mushrooms at home?
Home cultivation is not permitted for commercial distribution, but personal cultivation of a single mature fruiting body for personal use is not expressly prohibited. The Department of Health’s forthcoming guidelines are expected to clarify permissible cultivation limits; until then, growers should assume that any cultivation beyond a single specimen could be interpreted as a felony.
How does the law address accidental ingestion or poisoning?
Act 190 does not create a legal defense for accidental ingestion, but the civil penalty structure allows first‑time offenders to receive a modest fine rather than criminal prosecution. Medical emergencies related to mushroom consumption are still treated as health matters, and emergency responders are encouraged to report cases to public health officials for data collection.
Will employers be able to test for psilocybin use?
Employers may still conduct drug testing that includes psilocybin screening, as the substance remains federally illegal. Positive results could lead to employment consequences, even though the state no longer criminalizes possession for adults.
Does the law affect research institutions in Vermont?
Research on psilocybin continues to require federal Schedule I approval from the DEA. The 2026 statute does not alter the federal licensing process, but the state’s more permissive stance may make it easier for universities to obtain state‑level approvals for observational studies and therapeutic trials.